Altintas O.Altintas M.O.Tasal A.Kucukdagli O.T.Asil T.2019-08-012019-08-0120160161-6412https://dx.doi.org/10.1080/01616412.2016.1215030https://hdl.handle.net/11480/1824Objectives: Of all strokes, 85% are ischemic and intracranial artery occlusion accounts for 80% of these ischemic strokes. Endovascular therapy for acute ischemic stroke was a new modality aiming at resolution of clots in occluded cerebral arteries. The platelet-to-lymphocyte ratio (PLR) was introduced as a potential marker to determine increased inflammation, which is a result of releasing many mediators from the platelets. In this study we aimed to evaluate whether the PLR had a prognostic role in stroke patients undergoing thrombectomy and attempted to determine the effect that this ratio had on their survival. Methods: Over a three-year period, demographic, clinical, and angiographic findings of 57 consecutive patients with acute ischemic stroke who underwent mechanical thrombectomy were evaluated. Results: The patients were divided into two groups on the basis of a PLR level cut-off value of 145 based on receiver operating characteristic (ROC) curve. Successful revascularization (mTICI 2b and 3) was achieved in 42 of 57 (73.7%) patients; a mTICI 3 state was observed in 21 of 23 patients with low-PLR values (p = .015). Patients with higher PLR values had significantly a score of less than six on the ASPECT scale compared to patients with lower PLR values (p = .005). The patients with low-PLR values had better functional outcomes (mRS ? 2) compared with the patients with high-PLR values [respectively, p = .004 (at first month) and p = .014 (at third month)]. Discussion: The platelet-to-lymphocyte ratio could represent pro-thrombotic inflammatory state in acute ischemic stroke patients because having a high-PLR values increased the poor prognosis, the rate of insufficient recanalization, and the size of infarcted area. © 2016 Informa UK Limited, trading as Taylor & Francis Group.eninfo:eu-repo/semantics/closedAccessAcute strokeEndovascular treatmentPatient outcomePlatelet/lymphocyte ratioArticle38975976510.1080/01616412.2016.121503027477691